CorMedix Inc. (NASDAQ:CRMD) Shares Sold by Nomura Holdings Inc.

Nomura Holdings Inc. reduced its position in CorMedix Inc. (NASDAQ:CRMD) by 0.2% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,946,552 shares of the company’s stock after selling 4,980 shares during the period. Nomura Holdings Inc. owned approximately 5.38% of CorMedix worth $11,079,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of the business. Steward Partners Investment Advisory LLC increased its stake in shares of CorMedix by 3.1% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 138,008 shares of the company’s stock worth $519,000 after buying an additional 4,195 shares during the last quarter. Advisor OS LLC grew its holdings in CorMedix by 20.0% during the 4th quarter. Advisor OS LLC now owns 30,000 shares of the company’s stock worth $113,000 after acquiring an additional 5,000 shares in the last quarter. Raymond James & Associates increased its position in shares of CorMedix by 15.7% in the 4th quarter. Raymond James & Associates now owns 42,827 shares of the company’s stock worth $161,000 after purchasing an additional 5,800 shares during the last quarter. Raymond James Financial Services Advisors Inc. raised its stake in shares of CorMedix by 14.5% in the 4th quarter. Raymond James Financial Services Advisors Inc. now owns 81,834 shares of the company’s stock valued at $308,000 after purchasing an additional 10,362 shares in the last quarter. Finally, Tower Research Capital LLC TRC lifted its position in shares of CorMedix by 325.5% during the fourth quarter. Tower Research Capital LLC TRC now owns 13,981 shares of the company’s stock worth $53,000 after purchasing an additional 10,695 shares during the last quarter. 34.18% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

CRMD has been the topic of a number of research analyst reports. JMP Securities reaffirmed a “market outperform” rating and set a $19.00 target price on shares of CorMedix in a report on Tuesday, April 9th. Needham & Company LLC reissued a “buy” rating and set a $10.00 price target on shares of CorMedix in a research report on Monday, May 13th. Finally, Royal Bank of Canada reduced their price objective on CorMedix from $10.00 to $9.00 and set an “outperform” rating on the stock in a research note on Wednesday, March 13th.

CorMedix Stock Down 3.6 %

CRMD opened at $4.33 on Wednesday. The company’s 50-day moving average price is $5.28 and its 200 day moving average price is $4.18. CorMedix Inc. has a fifty-two week low of $2.57 and a fifty-two week high of $7.00. The firm has a market cap of $237.98 million, a price-to-earnings ratio of -4.66 and a beta of 1.73.

CorMedix (NASDAQ:CRMD) last announced its quarterly earnings results on Thursday, May 9th. The company reported ($0.25) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.02. Research analysts anticipate that CorMedix Inc. will post -0.85 earnings per share for the current year.

About CorMedix

CorMedix Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure.